Background {#Sec1}
==========

Vascular endothelial growth factor (VEGF), located on chromosome 6 (6p21.1) and a key regulator of vascular formation, is initially characterized by its actions on the endothelial fenestration and maintains permeability of capillary vessels, inducing vasculogenesis, angiogenesis \[[@CR1], [@CR2]\]. VEGF, an essential growth factor, is involved in the glomerular development and the postnatal homeostasis, and it is secreted by podocytes into the primary urine in high amounts, back-filtered across the glomerular capillary wall to act on the endothelial cells \[[@CR3]\]. VEGF can repair interstitial tubule compartment in the cyclosporine nephrotoxicity, but the mRNA level of VEGF has been up-regulated in the tubules in hypoxic states \[[@CR2]\]. VEGF gene polymorphism can affect the activation of VEGF, and there are some studies find that VEGF gene polymorphism is associated with SLE risk.

Systemic lupus erythematosus (SLE), characterized by the formation of immune complexes with nuclear antigens and the production of antibodies to components of the cell nucleus (antinuclear antibodies or ANAs) \[[@CR4]\], is a prototypic and heterogeneous autoimmune disease with a wide clinical expression \[[@CR5]\], and presents highly heterogeneous clinical manifestations and multi-systemic involvement \[[@CR6]\]. Lupus nephritis (LN) is one of the most frequent and crucial complication of SLE, considered as the major predictor of poor prognosis \[[@CR7]\]. Some factors were reported that gene expression, protein expression, and gene polymorphism were associated with the risk of some diseases \[[@CR8]--[@CR12]\]. Furthermore, results from meta-analysis are more robust when compared to individual study. There was no meta-analysis to assess the relationship between VEGF levels / VEGF gene polymorphism and SLE risk, and the association of VEGF with SLE developing into LN. In this study, we widely collected the related research on these relationships and used meta-analysis method to pool the results.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

The retrieval strategy of vascular endothelial growth factor, VEGF, systemic lupus erythematosus, SLE, lupus nephritis and LN were entered into China Biological Medicine Database (CBM), and PubMed on June 10, 2018, without language limitations. We also checked the references cited in the recruited articles for additional reports.

Inclusion and exclusion criteria {#Sec4}
================================

Inclusion criteria {#Sec5}
------------------

\(1\) The study should be a case-control study; (2) The outcome should be SLE or LN; (3) There were two groups (case group vs control group). (4) Levels of VEGF should be detected by enzyme-linked immunosorbent assay (ELISA).

Exclusion criteria {#Sec6}
------------------

\(1\) Case reports, editorials and review articles; (2) Articles did not provide the VEGF levels or detail genotype data; (3) Association of VEGF genotype / VEGF level with other diseases which were not related to SLE or LN. (4) non-traditional ELISA method for the determination of VEGF levels, such as sandwich ELISA test.

Data extraction and synthesis {#Sec7}
-----------------------------

Data and information from each investigation was extracted independently by at least 2 investigators: the surname of first author, publication year, VEGF protein levels, and the sample number of case group and control group for VEGF genotypes. The frequencies of alleles were counted for the SLE group and the control group. The results were compared and disagreements were resolved by discussion.

The diagnosis of SLE was based on according to ACR (American College of Rheumatology) criteria \[[@CR13]\]. Active SLE was defined as follows: disease activity score of SLE was evaluated by the systemic lupus erythematosus disease activity index (SLEDAI) score, and a patient was diagnosed as active if SLEDAI score was higher than or equals to 10 \[[@CR14]\].

Statistical analysis {#Sec8}
--------------------

Available data was analyzed using Cochrane Review Manager Version 5 (Cochrane Library, UK). When the *P* value of heterogeneity test was more than 0.1, the pooled statistic was counted using the fixed effects model, otherwise, a random effects model was conducted. Odds ratios (OR) was used to express the results for dichotomous data and mean differences (MD) was used to express the results for continuous data, and 95% confidence intervals (CI) were also counted. A *p*-value of 5% or lower was considered to be statistically significant, and I^2^ was used to test the heterogeneity among recruited studies.

Results {#Sec9}
=======

Search results {#Sec10}
--------------

Fifteen articles \[[@CR14]--[@CR28]\] were related to VEGF levels in SLE vs control in this meta-analysis, including 573 SLE patients and 436 controls (Table [1](#Tab1){ref-type="table"}). Six reports \[[@CR14], [@CR22], [@CR23], [@CR25], [@CR26], [@CR28]\] were included for the meta-analysis of Active SLE vs Inactive SLE. Two studies \[[@CR16], [@CR27]\] were recruited for the meta-analysis of LN vs SLE without LN. Three reports \[[@CR29]--[@CR31]\] were included for the analysis of the effect of VEGF -634G/C gene polymorphism (rs2010963) on SLE risk, including 523 SLE patients and 550 controls.Table 1characteristics of the studies for the relationship between VEGF levels (pg/ml) and SLE riskAuthor, yearCountrySex (F/M)Age (Years)SLEControlSLEControlSLEControlMeanSDNMeanSDNNavarro 2002Mexico24/419/536.6 ± 16.129.2 ± 8.570.25168.262823.48153.724Heshmat 2007Egypt24/129/114.1 ± 2.614 ± 2.5579.5184.725113.230.830Kuryliszyn-Moskal 2007Poland44/3NC40.8 ± 13.6NC225187.54415014030Tanaseanu 2007Romania12/3NC35 ± 15NC744.2425.115330.384.1610Ciprandi 2008Italy40/033/741.95 ± 8.343 ± 8.2662.570040500512.540Colombo 2009Italy80/080/042.6 ± 9.140.1 ± 9.5307.9292.280120.7118.480Kuryliszyn-Moskal 2009Poland76/4NC39.5 ± 13.3NC355.9292.247144.654.433Edelbauer 2012Austria17/65/1515 ± 512 ± 3216281440920Robak 2013Poland55/517/339.2 ± 27.5NC431.9311.660202.5117.620Willis 2014USA18/327/544.6 ± 25.5NC453.99261.1921113.5888.2932Zhou 2014China50/422/636.81 ± 12.5237.82 ± 12.8691.47108.675447.2952.6228Bărbulescu 2015Romania16/216/145 ± 10.81NC68.9971.061831.8411.7417Liu 2015China59/1631/935.42 ± 11.7933.62 ± 10.21327.5702.5575172.9207.4540Ghazali 2017Malaysia44/226/032.39 ± 11.4633.19 ± 10.30553.65398.6446343198.2126Merayo-Chalico 2018MexicoNCNC34.6 ± 4.236 ± 4.165327562231166Note: *VEGF* vascular endothelial growth factor, *SLE* systemic lupus erythematosus, *SD* standard deviation, *N* the total number of SLE group or control group, *Control* healthy controls, *F/M* female/male, *NC* not clear

Association of VEGF with SLE risk {#Sec11}
---------------------------------

In this meta-analysis, we found that VEGF levels was associated with SLE risk (MD =196.02, 95% CI: 135.29--256.75, *P* \< 0.00001; Fig. [1](#Fig1){ref-type="fig"}). The *p*-value of the heterogeneity test was \< 0.00001. Thus, a random effects model was conducted.Fig. 1Association of vascular endothelial growth factor protein levels with SLE risk. SLE: systemic lupus erythematosus; SD: standard deviation; Total: the total number of SLE group or control group; CI: confidence intervals; I^2^: test the heterogeneity among recruited studies; df: degrees of freedom

Association of VEGF with active SLE risk {#Sec12}
----------------------------------------

In this meta-analysis, we found that VEGF levels was associated with active SLE risk (MD =77.51, 95% CI: 10.98--144.05, *P* = 0.02; Fig. [2](#Fig2){ref-type="fig"}). The *p*-value of the heterogeneity test was \< 0.00001. Thus, a random effects model was conducted.Fig. 2Association of vascular endothelial growth factor protein levels with active SLE risk. SLE: systemic lupus erythematosus; SD: standard deviation; Total: the total number of SLE group or control group; CI: confidence intervals; I^2^: test the heterogeneity among recruited studies; df: degrees of freedom

Association of VEGF with SLE developing into LN {#Sec13}
-----------------------------------------------

In this meta-analysis, we found that VEGF levels was associated with SLE developing into LN risk (MD =223.16, 95% CI: 144.38--301.93, *P* \< 0.00001; Fig. [3](#Fig3){ref-type="fig"}). The *p*-value of the heterogeneity test was 0.25. Thus, a fixed effects model was conducted.Fig. 3Association of vascular endothelial growth factor protein levels with SLE developing into LN. SLE: systemic lupus erythematosus; LN: Lupus nephritis; SD: standard deviation; Total: the total number of SLE group or control group; CI: confidence intervals; I^2^: test the heterogeneity among recruited studies; df: degrees of freedom

Association of the VEGF -634G/C gene polymorphism with SLE susceptibility {#Sec14}
-------------------------------------------------------------------------

In this meta-analysis, we found that VEGF -634G/C gene polymorphism was not associated with SLE risk (C allele: OR = 0.96, 95% CI: 0.81--1.15, *P* = 0.66; CC genotype: OR = 0.91, 95% CI: 0.65--1.29, *P* = 0.61; GG genotype: OR = 1.03, 95% CI: 0.80--1.33, *P* = 0.80; Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Association between vascular endothelial growth factor -634G/C gene polymorphism (rs2010963) with SLE susceptibility. SLE: systemic lupus erythematosus; M-H: Mantel-Haenszel; Total: the total number of SLE group or control group; CI: confidence intervals; I^2^: test the heterogeneity among recruited studies; df: degrees of freedom

Discussion {#Sec15}
==========

In this study, we found that VEGF levels was associated with SLE risk, and VEGF levels was associated with active SLE risk. We also found that VEGF levels was associated with SLE developing into LN risk. It indicated that VEGF was associated with the SLE risk, the activation of SLE, and the SLE progression. The sample size for the meta-analysis on the relationship between VEGF levels and SLE risk was larger, and the results might be robust. SLE is an autoimmune disease, associated with the primary site represented by vascular endothelial cell injury, and VEGF has been regarded as a key mediator of modulator of neovascularization and endothelial dysfunction. We speculated that the increased VEGF protein levels was associated with the SLE vascular inflammation and associated with SLE risk. However, more studies should be performed to confirm it.

There were some meta-analyses to detect the association between VEGF expression and diseases. Huang et al. \[[@CR32]\] included nine articles met the inclusion criteria for our meta-analysis to examine the relationship between the protein expression of VEGF and lymph node metastasis (LNM) in papillary thyroid cancer, and reported that LNM occurred more frequently in papillary thyroid cancer patients with high VEGF expression than in those with low VEGF expression. Fafliora et al. \[[@CR33]\] included 11 studies in the meta-analysis, and reported that VEGF levels in patients with malignant pleural effusion were increased as compared to the patients with benign pleural effusion. Lee et al. \[[@CR34]\] conducted a meta-analysis of the VEGF levels in patients with rheumatoid arthritis and controls including 13 studies, and found that significantly higher circulating VEGF levels in patients with rheumatoid arthritis and a positive correlation between VEGF levels and disease activity in rheumatoid arthritis. VEGF levels might be a predicted factor for some diseases. In our meta-analysis, we also found that VEGF was associated with SLE risk and SLE progression.

In this study, we also conducted the meta-analysis for the association of VEGF gene polymorphism with SLE susceptibility, and we found that VEGF -634G/C gene polymorphism (rs2010963) was not associated with SLE risk. There was no other meta-analysis to assess this relationship. However, there was only three reports included for the analysis of the effect of VEGF -634G/C gene polymorphism on SLE risk. This result must be treated with caution. More studies should be conducted to confirm the results in the future. We speculated that the VEGF -634G/C gene polymorphism was not associated with the VEGF levels or the activity of VEGF, and it was not associated with SLE risk. However, more investigations should be conducted to confirm it.

In previous, there were some meta-analysis conducted to assess the relationship between VEGF -634G/C gene polymorphism and diseases. Zhuang et al. \[[@CR35]\] included nine investigations with 2281 cases with gastric cancer and 2820 controls for meta-analysis, and reported that VEGF -634G/C G allele carrier may increase gastric cancer risk. Gong et al. \[[@CR36]\] included six studies in their meta-analysis, and reported that the VEGF -634G/C gene polymorphism was not associated with an increased risk for renal cell carcinoma. Malik et al. \[[@CR37]\] included six case-control studies for meta-analysis, and suggested that VEGF-634G/C gene polymorphism might not be associated with retinopathy of prematurity risk. In our meta-analysis, we found that VEGF -634G/C gene polymorphism was not associated with SLE risk.

Conclusions {#Sec16}
===========

In this study, we found that VEGF levels was associated with SLE risk, active SLE risk and SLE developing into LN risk. However, VEGF -634G/C gene polymorphism was not associated with SLE risk.
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